BIO Gets Pep Talk From Commander-In-Chief; Is Boom-And-Bust Cycle Over?
Executive Summary
The recent rebound in the biotechnology sector is "for real," FDA Commissioner McClellan declared during the Biotechnology Industry Organization annual meeting in Washington, D.C. June 23
You may also be interested in...
“Project BioShield” Offers Funding Source For Biotech, McClellan Tells BIO
The biotechnology industry should embrace Project BioShield as a guaranteed market for innovative counter-terrorism technologies, Commissioner McClellan said during the Biotechnology Industry Organization CEO and investor conference Feb. 27 in New York
McKesson Splits CEO Into Operations & Strategy: Hammergren & Mahoney
McKessonHBOC is relying on two young McKesson execs acting as a two-person CEO office to drive the integration of distribution and information businesses into a company able to link each episode of care from first patient contact to prescription dispensing.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011